DEUTSCHE BANK AG\ - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 21 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.7%.

Quarter-by-quarter ownership
DEUTSCHE BANK AG\ ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q2 2020$1,042,000
-26.5%
1,082,000
-26.7%
0.00%0.0%
Q1 2020$1,417,000
+15.3%
1,476,000
+19.0%
0.00%
Q2 2018$1,229,000
-36.7%
1,240,000
-13.9%
0.00%
-100.0%
Q2 2017$1,943,0001,440,0000.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q2 2017
NameSharesValueWeighting ↓
LINDEN ADVISORS LP 71,957,000$88,374,0003.14%
Context Capital Management, LLC 3,500,000$4,288,0002.87%
Mohican Financial Management, LLC 1,000,000$1,250,0002.40%
Verition Fund Management LLC 8,000,000$9,835,0000.79%
ZAZOVE ASSOCIATES LLC 8,170,000$10,024,0000.51%
Baupost Group 30,000,000$37,125,0000.46%
WOLVERINE ASSET MANAGEMENT LLC 24,020,000$29,431,0000.33%
SSI INVESTMENT MANAGEMENT LLC 3,007,000$3,683,0000.31%
CSS LLC/IL 2,900,000$3,556,0000.17%
Rock Springs Capital Management LP 1,500,000$1,844,0000.08%
View complete list of THERAVANCE BIOPHARMA INC shareholders